Realizing the Potential of CRISPR Gene Editing

<p>The Innovative Genomics Institute; a partnership between the University of California, Berkeley and the University of California, San Francisco led by Nobel laureate Jennifer Doudna; is working to harness CRISPR-based genome editing to correct underlying mutations in monogenic diseases. The institute is initially focusing its efforts on sickle cell disease and a rare familial autoimmune disorder. We spoke to Fyodor Urnov, director of technology and translation at the Innovative Genomics Institute, about its efforts to advance genome editing technology, its work on sickle cell disease; and why it is critical for researchers to consider issues like access, affordability, and scalability in developing genetic medicines. This episode is part of our ongoing Platforms of Hope series. <em>Thanks to&nbsp;</em><a href="https://www.pfizer.com/" rel="noopener noreferrer" target="_blank"><em>Pfizer, Inc</em></a><em>.,&nbsp;</em><a href="https://www.bluebirdbio.com/" rel="noopener noreferrer" target="_blank"><em>Bluebird</em></a><em>, and&nbsp;</em><a href="https://www.novartis.com/our-company/novartis-pharmaceuticals/novartis-gene-therapies" rel="noopener noreferrer" target="_blank"><em>Novartis Gene Therapies</em></a><em>&nbsp;for their support of this podcast, part of our&nbsp;</em><a href="https://globalgenes.org/platforms-of-hope-advances-in-gene-therapy-and-gene-editing/" rel="noopener noreferrer" target="_blank"><em>Platforms of Hope: Advances in Gene Therapy and Gene Editing</em></a><em>&nbsp;series.</em></p>